Navigation Links
NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
Date:7/24/2009

orm Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; enrollment in, outcomes and interpretation of the results of clinical trials; the timing of the submission of clinical trial data; acceptance of clinical trial data by the FDA in support of regulatory approval; and the tolerability profile and/or benefits of its product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to; positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.                     The Ruth Group
    Stephen Ghiglieri                   Sara Pellegrino (investors)
    Chief Financial Officer             (646) 536-7002
    (650) 358-3310                      spellegrino@theruthgroup.com

                                        Jaso
'/>"/>
SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
2. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
3. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
4. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
5. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
6. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
9. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
10. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
11. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
(Date:11/26/2014)... 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... appointment of Ms. Rebecca Yingnan Zhang as ... Ms.Zhang has over 20 years of experience in ... Prior to Ms. Zhang,s appointment as the Company,s Chief ...
(Date:11/24/2014)... SEATTLE , Nov. 24, 2014 ... granted Breakthrough Therapy Designation to the company,s JCAR015 ... for the treatment of relapsed or refractory B-cell ... collaboration partner, Memorial Sloan Kettering Cancer Center, where ... "The FDA,s action is important news ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
... Cardiac Science Corporation , a global leader in automated ... monitoring devices that connect to electronic medical record ... it has completed certification with Allscripts Professional ... connectivity solution for its resting ECG, stress, and Holter ...
... and Drug Commissioner Dr. Margaret Hamburg today conducted an unusual ... a forum hosted by the National Organization for Rare Disorders ... Hamburg could share with the patient advocates her vision for ... concerns. "I come today to ask for your ...
Cached Medicine Technology:Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 2Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 3Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 4Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 5NORD Hosts Forum for FDA Commissioner and Patient Leaders 2
(Date:11/26/2014)... Youngsters who enter puberty early are at increased risk ... was linked with a number of factors associated with ... according to the researchers. Early puberty was also linked ... peers, and having friends who were prone to getting ... found an association between early puberty and these factors, ...
(Date:11/26/2014)... Nov. 25, 2014 (HealthDay News) -- Teens prescribed ... to abuse those drugs than other teens, a ... need to conduct substance abuse assessments on teenagers ... said. "Prescribers and parents don,t realize the ... professor at the University of Michigan School of ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Exposure to peanut protein ... allergy in infants with the skin condition eczema, a ... children in the United States are allergic to peanuts. ... food allergies, particularly peanut allergy, the researchers noted. ... to 15 months. The researchers examined the amount of ...
(Date:11/26/2014)... Randy Dotinga HealthDay Reporter ... as Prilosec and Nexium may disrupt the makeup of bacteria ... and other problems, a small new study suggests. ... likely users will become ill, and study authors aren,t recommending ... However, these antacids "should be used at the lowest dose ...
(Date:11/24/2014)... Recently, Fecbek.com ( http://www.fecbek.com ), a leading ... and introduced the history of the Black Friday to its ... after Thanksgiving? It is the Black Friday! It is a ... 11th in China. However, not everyone knows the history of ... about this special day. , The fourth Friday in November ...
Breaking Medicine News(10 mins):Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3
... North Carolina (UNC) at Chapel Hill have revealed that inhaling ... by cystic fibrosis (CF). Hypertonic saline// is a water-based ... ,The researchers arrived at this conclusion after testing 24 patients ... inhaling the salt solution improved the health of the lungs ...
... Pharmaceutical companies have been called upon to stop marketing ... Organization (WHO), as the parasite which causes malaria may ... Kochi, director of the WHO's malaria department, said that ... effective anti-malarials, on its own would result in the ...
... experts have warned that the new wristwatch invented by South ... can turnout to be a health hazard. They have warned ... HIV/AIDS.// There are some who have also expressed doubts if ... ,'In my mind it's a potential public health ...
... 1.107 million fowl have been killed in Turkey with the ... in the country. This has been revealed by the Turkish ... detected in as many as 13 provinces in the country, ... the bird flu has been detected are Van, Aydin, Bursa, ...
... by having their ovaries and uterus removed, if they have ... is because these women face higher chances of contracting ovarian ... as high as 40% to 60%, while it is between ... ,Women who do not have the Lynch syndrome ...
... of African Subcommittee, House Committee on International Relations has ... AIDS testing and counseling as done in Uganda. //Uganda ... effective in early diagnosis of HIV and also helps ... person due to ignorance about the disease. ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: